|Bid||215.39 x 1100|
|Ask||221.00 x 800|
|Day's range||215.76 - 223.99|
|52-week range||166.30 - 244.99|
|Beta (5Y monthly)||1.14|
|PE ratio (TTM)||16.92|
|Earnings date||27 Apr 2020 - 03 May 2020|
|Forward dividend & yield||6.40 (2.87%)|
|Ex-dividend date||12 Feb 2020|
|1y target est||246.05|
J&J (JNJ) seeks approval for new Darzalex combo regimen in the United States to treat relapsed/refractory multiple myeloma patients who have received one to three prior lines of therapy.
The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...
Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
Amgen (AMGN) stock declines despite better-than-expected fourth-quarter 2019 results. Its 2020 earnings guidance falls short of expectations.
Amgen (AMGN) delivered earnings and revenue surprises of 5.81% and 3.18%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Q4 GDP hit the tape ahead of today's opening bell, with results better than analysts had been predicting: +2.1% was 30 basis points higher than the 1.8% expected.